Paolo Bironzo

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Brendan Bulik‐Sullivan, Jennifer Busby, Christine D. Palmer et al. · Nature Biotechnology · 2018 · 310 citations

Medicine, Molecular Biology, Oncology +17

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi et al. · Journal of Clinical Oncology · 2023 · 225 citations · Full text

Medicine, Oncology, Pharmacology +14

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes et al. · The Lancet Respiratory Medicine · 2018 · 222 citations · Full text

Medicine, Oncology, Epigenetics +16

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti et al. · Cancer Discovery · 2023 · 181 citations · Full text

Medicine, Molecular Genetics, Oncology +17